- Home
- Publications
- Publication Search
- Publication Details
Title
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
Authors
Keywords
-
Journal
Current Atherosclerosis Reports
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-07-29
DOI
10.1007/s11883-022-01057-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance
- (2022) Paul F. Lebeau et al. Nature Communications
- Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity
- (2022) Rachid Essalmani et al. JOURNAL OF VIROLOGY
- Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition
- (2022) Huimin Sun et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Evaluation of the distribution and excretion of [14C]-inclisiran following single subcutaneous administration in cynomolgus monkeys
- (2022) Dario Lehoux et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction
- (2022) Stephen J. Nicholls et al. JACC-Cardiovascular Imaging
- Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial
- (2022) Petr Ostadal et al. Lancet Diabetes & Endocrinology
- PCSK9 and LRP6: potential combination targets to prevent and reduce atherosclerosis
- (2022) Saskia R. Desita et al. Journal of Basic and Clinical Physiology and Pharmacology
- Statin use and clinical outcomes in patients with COVID-19: An updated systematic review and meta-analysis
- (2021) Rimesh Pal et al. POSTGRADUATE MEDICAL JOURNAL
- Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling
- (2021) Juanjuan Yuan et al. Protein & Cell
- In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates
- (2021) Kiran Musunuru et al. NATURE
- An oral antisense oligonucleotide for PCSK9 inhibition
- (2021) Peter Gennemark et al. Science Translational Medicine
- Substantial PCSK9 inactivation in β-cells does not modify glucose homeostasis or insulin secretion in mice
- (2021) Marie-Line Peyot et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- How Do Enveloped Viruses Exploit the Secretory Proprotein Convertases to Regulate Infectivity and Spread?
- (2021) Nabil G. Seidah et al. Viruses-Basel
- Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players
- (2021) Patrice Marques et al. BIOMEDICINE & PHARMACOTHERAPY
- PCSK9 Inhibition-Based Therapeutic Approaches: An Immunotherapy Perspective
- (2021) Amir Abbas Momtazi-Borojeni et al. CURRENT MEDICINAL CHEMISTRY
- The Multifaceted Biology of PCSK9
- (2021) Nabil G Seidah et al. ENDOCRINE REVIEWS
- The role of PCSK9 in inflammation, immunity, and autoimmune diseases
- (2021) Johan Frostegård Expert Review of Clinical Immunology
- A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors
- (2021) Thomas J. Tucker et al. JOURNAL OF MEDICINAL CHEMISTRY
- PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs
- (2021) Meryl Roudaut et al. Stem Cell Reports
- Inhibition of proprotein convertase subtilisin/kexin type 9 attenuates 2,4,6‐trinitrobenzenesulfonic acid‐induced colitis via repressing toll‐like receptor 4/nuclear factor‐kappa B
- (2020) Lei Lei et al. KAOHSIUNG JOURNAL OF MEDICAL SCIENCES
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
- (2020) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating Rather Than Intestinal PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Regulates Postprandial Lipemia in Mice
- (2020) Damien Garçon et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19
- (2020) Xiao-Jing Zhang et al. Cell Metabolism
- Evolocumab, a PCSK9‐Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia
- (2020) Thorsten M. Leucker et al. Journal of the American Heart Association
- Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy
- (2020) Prakash Deedwania et al. JAMA Cardiology
- Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes
- (2020) Esther Shuyi Gan et al. JOURNAL OF CLINICAL INVESTIGATION
- The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and GRP94 and protects against liver injury
- (2020) Paul F. Lebeau et al. JOURNAL OF CLINICAL INVESTIGATION
- Clinical implications and outcomes of the ORION Phase III trials
- (2020) Julia Brandts et al. Future Cardiology
- Novel strategies to target PCSK9: beyond monoclonal antibodies
- (2019) Nabil G Seidah et al. CARDIOVASCULAR RESEARCH
- Cholesterol-Lowering Agents
- (2019) Robert S. Rosenson et al. CIRCULATION RESEARCH
- Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
- (2019) Kausik K Ray et al. Lancet Diabetes & Endocrinology
- Loss-of-function PCSK9 mutants evade the unfolded protein response sensor GRP78 and fail to induce endoplasmic reticulum stress when retained
- (2018) Paul Lebeau et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PCSK9 plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque
- (2018) A. Liu et al. JOURNAL OF INTERNAL MEDICINE
- Coronary Endothelial Dysfunction Is Associated With Elevated Serum PCSK9 Levels in People With HIV Independent of Low‐Density Lipoprotein Cholesterol
- (2018) Thorsten M. Leucker et al. Journal of the American Heart Association
- Transcriptome Analysis Reveals Nonfoamy Rather Than Foamy Plaque Macrophages Are Proinflammatory in Atherosclerotic Murine Models
- (2018) Kyeongdae Kim et al. CIRCULATION RESEARCH
- The Reelin Receptors Apolipoprotein E receptor 2 (ApoER2) and VLDL Receptor
- (2018) Paula Dlugosz et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism
- (2017) Matteo Pirro et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Can iPCSK9-induced hypocholesterolemia starve cancer cells?
- (2017) Anne Gangloff et al. Journal of Clinical Lipidology
- A wild-type mouse-based model for the regression of inflammation in atherosclerosis
- (2017) Michael Peled et al. PLoS One
- Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain
- (2016) Steve Poirier et al. PLoS One
- PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse LiverSignificance
- (2015) Annie Demers et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Cross-talk between LOX-1 and PCSK9 in vascular tissues
- (2015) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9
- (2015) Quoc-Tuan Le et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: Evidence for genotype-specific regulation of lipoprotein metabolism
- (2015) Simon H. Bridge et al. JOURNAL OF HEPATOLOGY
- GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation
- (2015) Steve Poirier et al. Cell Reports
- Combined Administration of RG7652, a Recombinant Human Monoclonal Antibody Against PCSK9, and Atorvastatin Does Not Result in Reduction of Immune Function
- (2014) Thomas R. Gelzleichter et al. TOXICOLOGICAL SCIENCES
- PCSK9 acts as a chaperone for the LDL receptor in the endoplasmic reticulum
- (2013) Thea Bismo Strøm et al. BIOCHEMICAL JOURNAL
- The global distribution and burden of dengue
- (2013) Samir Bhatt et al. NATURE
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)
- (2013) Maryssa Canuel et al. PLoS One
- Familial Hypercholesterolemia and Atherosclerosis in Cloned Minipigs Created by DNA Transposition of a Human PCSK9 Gain-of-Function Mutant
- (2013) R. H. Al-Mashhadi et al. Science Translational Medicine
- PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages
- (2012) ZHIHAN TANG et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- The M2 Module of the Cys-His-rich Domain (CHRD) of PCSK9 Protein Is Needed for the Extracellular Low-density Lipoprotein Receptor (LDLR) Degradation Pathway
- (2012) Yascara Grisel Luna Saavedra et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Loss- and Gain-of-function PCSK9 Variants
- (2012) Suzanne Benjannet et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of a New Role of Human Resistin in Hepatocyte Low-Density Lipoprotein Receptor Suppression Mediated in Part by Proprotein Convertase Subtilisin/Kexin Type 9
- (2012) Michelle Melone et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The biology and therapeutic targeting of the proprotein convertases
- (2012) Nabil G. Seidah et al. NATURE REVIEWS DRUG DISCOVERY
- Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue
- (2011) Anna Roubtsova et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Novel Loss-of-Function PCSK9 Variant Is Associated with Low Plasma LDL Cholesterol in a French-Canadian Family and with Impaired Processing and Secretion in Cell Culture
- (2011) J. Mayne et al. CLINICAL CHEMISTRY
- Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH
- (2011) Paola Lo Surdo et al. EMBO REPORTS
- Increased Secretion of Lipoproteins in Transgenic Mice Expressing Human D374Y PCSK9 Under Physiological Genetic Control
- (2010) Bronwen Herbert et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The role of resistin as a regulator of inflammation: Implications for various human pathologies
- (2009) Mária Filková et al. CLINICAL IMMUNOLOGY
- Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation
- (2009) Steve Poirier et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started